Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Login Sign up free
Home Screener Maps Charts News Groups Insider Futures Forex Crypto Portfolio Calendar
Pricing
Market News Market Pulse Stocks News ETF News Crypto News

Structure Therapeutics Inc.

Contributing Author

Recent Articles by Structure Therapeutics Inc.

Sep-08
Structure Therapeutics Reports Positive Clinical Data Across Oral Small Molecule Amylin and GLP-1 Programs for Chronic Weight Management GPCR -14.70% GlobeNewswire
Sep-03
Structure Therapeutics to Participate in Upcoming Healthcare Investor Conferences GPCR GlobeNewswire
Aug-06
Structure Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights GPCR GlobeNewswire
Jun-05
Structure Therapeutics Announces Publication in Nature Medicine Highlighting Phase 2b ACCESS Program of Aleniglipron for Obesity GPCR GlobeNewswire
May-26
Structure Therapeutics Announces Participation in Upcoming Investor Conferences GPCR GlobeNewswire
May-07
Structure Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights GPCR GlobeNewswire
Apr-27
Structure Therapeutics to Present Aleniglipron, Amylin and Combination Data at the American Diabetes Association 86th Scientific Sessions GPCR GlobeNewswire
Apr-14
Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel GPCR GlobeNewswire
Mar-16
Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron GPCR +5.40% GlobeNewswire
Feb-26
Structure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights GPCR GlobeNewswire
Dec-17
Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity GPCR GlobeNewswire
Dec-11
Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional ADSs GPCR GlobeNewswire
Dec-09
Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants GPCR GlobeNewswire
Dec-08
Structure Therapeutics Announces Proposed $500 Million Public Offering of American Depositary Shares and Pre-Funded Warrants GPCR +102.49% GlobeNewswire
Dec-08
Structure Therapeutics Reports Positive Topline Data from ACCESS Program for its Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron GPCR +102.49% GlobeNewswire
Dec-07
Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025 GPCR GlobeNewswire
Nov-06
Structure Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights GPCR GlobeNewswire
Sep-02
Structure Therapeutics to Participate in Two Upcoming Healthcare Investor Conferences GPCR GlobeNewswire
Aug-06
Structure Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights GPCR GlobeNewswire
Jun-20
Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin Agonist, ACCG-2671 GPCR GlobeNewswire
May-29
Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences GPCR GlobeNewswire
May-08
Structure Therapeutics Reports First Quarter 2025 Financial Results and Recent Highlights GPCR GlobeNewswire
Affiliate • Advertise • API and Exports • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)